Speakers

Expand/Collapse

Dan Swerdlow
Senior Medical Director
Silence Therapeutics

Day One

Wednesday 2nd December 2020

8:00 am | Live Q&A & Discussion: Which organs are accessible and would be most valuable to target?

7:00 am | Validating Oligonucleotide Drug Targets Using Genomics, Molecular Phenotyping & Other ‘Big Data’

David Blakey
Chief Scientific Officer
MiNA Therapeutics

Day One

Wednesday 2nd December 2020

11:20 am | Live Q&A & Discussion: What Human & Animal Data is Important to Validate a Target?

10:00 am | Small Activating RNAs (saRNAs) for Treating Cardiometabolic Disease

Elena Feinstein
Chief Scientific Officer
Quark Pharmaceuticals

Day One

Wednesday 2nd December 2020

11:20 am | Live Q&A & Discussion: What Human & Animal Data is Important to Validate a Target?

Marcus Schindler
Senior Vice President, Head of Global Drug Discovery
Novo Nordisk

Marie Wikström Lindholm
Vice President, Head of Molecular Design
Silence Therapeutics

Day One

Wednesday 2nd December 2020

2:30 pm | Afternoon Break & Panel Discussion

Patrik Andersson
RNA Therapeutics Safety Lead
AstraZeneca

Day One

Wednesday 2nd December 2020

2:00 pm | Live Q&A & Discussion: Finding Ligands & Receptors That Display Desired Characteristics

1:00 pm | Oligo Therapeutics for Cardiovascular & Metabolic Disease – Challenges & Opportunities from a Safety Perspective

Piotr Kowalski
HRB Emerging Investigator for Health, Lecturer in Advanced Therapies
University College Cork

Day One

Wednesday 2nd December 2020

2:30 pm | Afternoon Break & Panel Discussion

2:00 pm | Live Q&A & Discussion: Finding Ligands & Receptors That Display Desired Characteristics

1:20 pm | Engineering of RNA Nanotherapeutics for Vascular Interventions

Richard Geary
Executive Vice President, Drug Development
Ionis Pharmaceuticals

Day One

Wednesday 2nd December 2020

2:30 pm | Afternoon Break & Panel Discussion

2:00 pm | Live Q&A & Discussion: Finding Ligands & Receptors That Display Desired Characteristics

1:40 pm | Translating Delivery of Antisense Oligonucleotides from Bench to Bedside

Robert Dullea
Senior Director, Internal Medicine Research Unit
Pfizer

Day One

Wednesday 2nd December 2020

4:10 pm | Live Q&A Transitioning From Hundreds to Hundreds of Thousands: How Realistic is Frequent Monitoring & Administration for Patients with Chronic Diseases?

3:30 pm | Vupanorsen, a Liver Targeted Angiopoietin-like 3 (ANGPTL3) Antisense Oligonucleotide (ASO), for the Reduction of Residual Cardiovascular Risk

Rusty Montgomery
Director of Research
miRagen Therapeutics

Day One

Wednesday 2nd December 2020

11:20 am | Live Q&A & Discussion: What Human & Animal Data is Important to Validate a Target?

11:00 am | De-risking miRNA-Targeting Therapeutics Through the Clinic

Samir Ounzain
Chief Executive Officer & Scientific Co-Founder
Co-Founder HAYA Therapeutics

Day One

Wednesday 2nd December 2020

8:00 am | Live Q&A & Discussion: Which organs are accessible and would be most valuable to target?

7:20 am | Next Generation Non-Coding Targets in Cardiometabolic Disease

Sandor Batkai
Head of Science & Co-Founder
Cardior Pharmaceuticals

Day One

Wednesday 2nd December 2020

11:20 am | Live Q&A & Discussion: What Human & Animal Data is Important to Validate a Target?

10:40 am | Overcoming Challenges Entering the Clinic

Tom Thuren
Metabolism Therapeutic Area Head, Cardio-Metabolic Development Unit
Novartis

Day One

Wednesday 2nd December 2020

4:10 pm | Live Q&A Transitioning From Hundreds to Hundreds of Thousands: How Realistic is Frequent Monitoring & Administration for Patients with Chronic Diseases?

3:50 pm | Oligonucleotides for Lowering LDL-C & Lp(a) – Two Different Approaches

Troels Koch
Chief Technology Officer, Senior Vice President Science & Technology
Inexos Therapeutics

Day One

Wednesday 2nd December 2020

8:00 am | Live Q&A & Discussion: Which organs are accessible and would be most valuable to target?

7:40 am | Coupling Biophysical & Biological Parameters to Maximize Oligonucleotide Uptake